Search
Nicotinamide
go.drugbank.com/drugs/DB02701ApprovedInvestigationalAn important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra.
Delandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigationalIt was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, ...
Thioproperazine
go.drugbank.com/drugs/DB01622ApprovedThioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually ...
Dexchlorpheniramine maleate
go.drugbank.com/drugs/DB09555ApprovedDexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
Ceritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalThis occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance.
Bevantolol
go.drugbank.com/drugs/DB01295InvestigationalBevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalIdebenone is a synthetic analogue of ubiquinone (also known as Coenzyme Q10), a vital cell antioxidant and essential component of the Electron Transport Chain (ETC).
Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigationalwas originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin approved to treat a human disease in the US
Treprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigational[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options.